GlassScriptPhysician profile
James A Arcoleo
NPI 1407885676
$17,402.03
in general payments reported to CMS, 2019-2025
57 companies · $1,725 in 2025
The $1,725 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,038 · 2020: $1,445 · 2021: $2,291 · 2022: $2,212 · 2023: $2,912 · 2024: $2,780 · 2025: $1,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,353 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,352.70 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,816.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,649.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,640.45 | 2019-2024 | Xarelto |
| Amgen INC. | $1,614.48 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,278.11 | 2019-2025 | Cardiomems, Mitraclip, Xience Sierra |
| Astrazeneca Pharmaceuticals LP | $1,168.82 | 2019-2025 | Lokelma, Wainua, Airsupra |
| Pfizer INC. | $1,055.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $992.41 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $948.54 | 2022-2024 | Symplicity G3, Micra, Evera Mri Xt Dr Surescan |
| Boston Scientific Corporation | $844.98 | 2019-2025 | Varithena Administration Pack, Watchman Access System, Patientcare Link |
| Novo Nordisk INC | $534.93 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.47 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $382.06 | 2019-2021 | |
| Bridgebio Pharma, INC. | $317.67 | 2025 | Attruby |
| Biosense Webster, INC. | $179.80 | 2024 | Carto 3 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Arcoleo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.